| Raphael S Orenstein, MD | |
|
120 William Penn Plz, Durham, NC 27704-2150 | |
| (919) 220-5255 | |
| (919) 220-6971 |
| Full Name | Raphael S Orenstein |
|---|---|
| Gender | Male |
| Speciality | Physical Medicine And Rehabilitation |
| Experience | 32 Years |
| Location | 120 William Penn Plz, Durham, North Carolina |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1154306819 | NPI | - | NPPES |
| 891072X | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208100000X | Physical Medicine & Rehabilitation | 9701091 (North Carolina) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Carolina Rehabilitation And Surgical Associates, Pa | 5597679605 | 42 |
News Archive
Scientists at the National Cancer Institute, have created a database of information about a group of genes associated with multidrug resistance in cancerous tumors.
A new publication illustrates the burden that chronic illnesses impose on American society, demonstrating through charts and graphics how 60 percent of American adults suffer from at least one chronic health condition and 42 percent have more than one.
A majority of the HIV-infected cells that persist in HIV-infected individuals even during suppressive antiretroviral therapy originated from cellular proliferation, not viral replication, according to new research published in Nature Communications.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 6 days ago
| Entity Name | Carolina Rehabilitation And Surgical Associates, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518913656 PECOS PAC ID: 5597679605 Enrollment ID: O20031113000494 |
News Archive
Scientists at the National Cancer Institute, have created a database of information about a group of genes associated with multidrug resistance in cancerous tumors.
A new publication illustrates the burden that chronic illnesses impose on American society, demonstrating through charts and graphics how 60 percent of American adults suffer from at least one chronic health condition and 42 percent have more than one.
A majority of the HIV-infected cells that persist in HIV-infected individuals even during suppressive antiretroviral therapy originated from cellular proliferation, not viral replication, according to new research published in Nature Communications.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Raphael S Orenstein, MD 120 William Penn Plz, Durham, NC 27704-2150 Ph: (919) 220-5255 | Raphael S Orenstein, MD 120 William Penn Plz, Durham, NC 27704-2150 Ph: (919) 220-5255 |
News Archive
Scientists at the National Cancer Institute, have created a database of information about a group of genes associated with multidrug resistance in cancerous tumors.
A new publication illustrates the burden that chronic illnesses impose on American society, demonstrating through charts and graphics how 60 percent of American adults suffer from at least one chronic health condition and 42 percent have more than one.
A majority of the HIV-infected cells that persist in HIV-infected individuals even during suppressive antiretroviral therapy originated from cellular proliferation, not viral replication, according to new research published in Nature Communications.
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, today announced preliminary data from a Phase II trial evaluating the safety and efficacy of farletuzumab in platinum-sensitive epithelial ovarian cancer subjects experiencing their first relapse. Farletuzumab (MORAb-003) is a humanized monoclonal antibody that targets the Folate Receptor Alpha (FRA).
› Verified 6 days ago
Elena Hart, MD Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 3643 N Roxboro St, Durham, NC 27704 Phone: 919-470-4000 | |
Dr. Carolyn Keeler, D.O. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: Dumc 3807, Durham, NC 27710 Phone: 919-684-7821 | |
Mazen Zein, D.O Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: Duke Medicine Circle Spine Center Clinic 1b/1c, Durham, NC 27710 Phone: 919-660-3006 | |
Shane Sullivan, Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 4221 Garrett Rd, Durham, NC 27707 Phone: 919-937-9607 | |
Dr. Paul Edwind Howell Jr., M.D. Physical Medicine & Rehabilitation Medicare: Medicare Enrolled Practice Location: 508 Fulton St # 117, Durham, NC 27705 Phone: 919-286-0411 Fax: 919-416-5913 | |
Eugenia Fay Zimmerman, M.D. Physical Medicine & Rehabilitation Medicare: Accepting Medicare Assignments Practice Location: 120 William Penn Plz, Durham, NC 27704 Phone: 919-220-5255 Fax: 919-220-6971 |